You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 32 No. 6, June 1975 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Acetazolamide Treatment of Hypokalemic Periodic Paralysis

Probable Mechanism of Action

Frederic Q. Vroom, MD; Maureen A. Jarrell; Thomas H. Maren, MD

Arch Neurol. 1975;32(6):385-392.


Abstract

Following administration of glucose and insulin to three patients with hypokalemic periodic paralysis, serum K fell 1.9 mM. After administration of acetazolamide, 250 mg four times daily, serum K fell 0.9 mM, a substantial difference. In normal persons glucose and insulin lowered serum K 0.5 mM, and this was not changed substantially by acetazolamide.

The metabolic acidosis induced by the drug appears to be responsible for the change in decrement of serum K and for the amelioration of symptoms in the patients. The findings agree with earlier reports that metabolic acidosis lowers the rate of entry of K± into muscle, thus opposing the heightened or pathological entry of K± into muscle cells during attacks of the disease.



Author Affiliations

From the departments of pharmacology and therapeutics and of medicine (neurology), University of Florida College of Medicine, Gainesville.


Footnotes

Accepted for publication Sept 3, 1974.

Reprint requests to Department of Pharmacology and Therapeutics, University of Florida College of Medicine, Box 728, JHM Health Center, Gainesville, FL 32610 (Dr. Maren).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A
Sternberg et al.
Brain 2001;124:1091-1099.
ABSTRACT | FULL TEXT  

Continuous muscle fibre activity: a case treated with acetazolamide
Celebisoy et al.
J. Neurol. Neurosurg. Psychiatry 1998;64:256-258.
ABSTRACT | FULL TEXT  

Dissociation of Glucose and Potassium Arterial-Venous Differences Across the Forearm by Acetazolamide: A Possible Relationship to Acetazolamide's Beneficial Effect in Hypokalemic Periodic Paralysis
Riggs et al.
Arch Neurol 1984;41:35-38.
ABSTRACT  

Hypokalemic Periodic Paralysis
Roeltgen
Arch Neurol 1979;36:453-453.
ABSTRACT  

Erythrocyte Membrane Studies in Familial Hypokalemic Periodic Paralysis
Buruma et al.
Arch Neurol 1978;35:615-616.
ABSTRACT  

Acetazolamide-Induced Weakness in Paramyotonia Congenita
RIGGS et al.
ANN INTERN MED 1977;86:169-173.
ABSTRACT  

The Effect of Acidosis in Hypokalemic Periodic Paralysis
Jarrell et al.
Arch Neurol 1976;33:791-793.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1975 American Medical Association. All Rights Reserved.